Floating-pulsatile Release Multiparticulate System for Chronopharmacotherapy: Effect of Some Hydrophobic Additives on the Buoyancy and Release Behavior of Particles

Abstract

A blend of floating and pulsatile principles of a drug delivery system would have the advantage that a drug can be released in the upper gastrointestinal (GI) tract after a lag period, which is anticipated for chronotherapy. In this study, microballoons were prepared by an emulsion solvent diffusion technique using Eudragit S100, and hydrophobic additive (magnesium stearate, stearic acid or talc) for time- and site-specific drug release of piroxicam. The effect of hydrophobic additives on the production yield of floating microparticles, buoyant ability for 8 h, release of drug in simulated GI fluids (simulated gastric fluid [SGF] and simulated intestinal fluid [SIF]), mean particle size, apparent particle density, encapsulation efficiency of drug and physical state of incorporated drug were studied. Both production yield and buoyancy of the microballoons were affected by additives in the following order: magnesium stearate, stearic acid>free-additive>talc. The observed difference in yield and the buoyancy of the microballoons could be attributed to the hydrophobic character of the additives and the shell rigidity of the obtained microballoons. Incorporation of hydrophobic additives in the microballoons was found to impart the desired release properties to the microballoons by providing a 2-phase release pattern with initial slow release (5–6%) through 8 h in SGF followed by rapid pulse release (>92%) in SIF through 15 min. The microballoons co-formulated with magnesium stearate or stearic acid, combining excellent buoyancy and suitable drug release pattern of piroxicam, could be useful in chronopharmacotherapy in arthritis.

Key words

chronopharmacotherapy - piroxicam - floating–pulsatile drug delivery system - microballoons

• References

• 1 Lemmer B. The clinical relevance of chronopharmacology in therapeutics. Pharmacol Res 1996; 33: 107-115
• 2 Mormont M, Levi F. Cancer chronotherapy: principles, applications, and perspectives. Cancer 2003; 97: 155-169
• 3 Smolensky MH. Chronobiology and chronotherapeutics: applications to cardiovascular medicine. Am J Hypertens 1996; 9: 11S-21S
• 4 Smolensky MH. Circadian rhythms in clinical medicine with application to hypertension. Am J Hypertens 2001; 14: 280S-290S
• 5 Lemmer B. Circadian rhythms and drug delivery. J Control Release 1991; 16: 63-74
• 6 Lemmer B. Chronopharmacokinetics: implications for drug treatment. J Pharm Pharmacol 1999; 51: 887-890
• 7 Kikuchi A, Okano T. Pulsatile drug release control using hydrogels, Adv. Drug Deliv Rev 2002; 54: 53-77
• 8 Gazzaniga A, Busetti C, Moro L et al. Evaluation of viscosity HPMC as retarding coating material in the preparation of a time-based oral colon specific delivery system. Proc Int Symp Control Rel Bioact Mater 1995; 22: 242-243
• 9 Niwa K, Takaya T, Morimoto T et al. Preparation and evaluation of a time-controlled release capsule made of ethylcellulose for colon delivery of drugs. J Drug Target 1995; 3: 83-89
• 10 Hoffman A, Stepensky D, Lavy E et al. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. Int J Pharm 2004; 277: 141-153
• 11 Badve SS, Sher P, Korde A et al. Development of hollow/porous calcium pectinate beads for floating-pulsatile drug delivery. Eur J Pharm Biopharm 2007; 65: 85-93
• 12 Sharma S, Pawar A. Low density multiparticulate system for pulsatile release of meloxicam. Int J Pharm 2006; 313: 189-197
• 13 Karavas E, Georgarakis E, Bikiaris D. Application of PVP/HPMC miscible blends with enhanced mucoadhesive properties for adjusting drug release in predictable pulsatile chronotherapeutics. Eur J Pharm Biopharm 2006; 64: 115-126
• 14 Stehlin I. A time to heal: chronotherapy tunes in to body’s rhythms. FDA Consumer magazine April 1997;
• 15 Crofford LJ, Kalogeras KT, Mastorakos G et al. Circadian relationships between interleukin (IL)-6 and hypothalamic-pitutary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocr Metab 1997; 82: 1279-1283
• 16 Cutolo M, Seriolo B, Craviotto C et al. Circadian rhythms in RA. Ann Rheum Dis 2003; 62: 593-596
• 17 Heynen G. Toleration and safety of piroxicam. Eur J Rheumatol Inflamm 1987; 8: 86-93
• 18 Sato Y, Kawashima Y, Takeuchi H et al. Physicochemical properties to determine the buoyancy of hollow microparticles (microparticles) prepared by the emulsion solvent diffusion method. Eur J Pharm Biopharm 2003; 55: 297-304
• 19 Kawashima Y, Niwa T, Takeuchi H et al. Hollow microparticles for use as a floating controlled drug delivery system in the stomach. J Pharm Sci 1992; 81: 35-140
• 20 Sato Y, Kawashima Y, Takeuchi H et al. In vitro evaluation of floating and drug releasing behaviors of hollow microspheres (microballoons) prepared by the emulsion solvent diffusion method. Europ J Pharm Biopharm 2004; 57: 235-243
• 21 Re MI, Biscans B. Preparation of microparticles of Ketoprofen with acrylic polymers by a quasi-emulsion solvent diffusion method. Powder Technol 1999; 101: 120-133
• 22 Zaniboni HC, Fell JT, Collett JH. Production and characterization of enteric beads. Int J Pharm 1995; 125: 151-155
• 23 Herzfeldt CD, Kummel R. Dissociation constants, solubilities and dissolution rates of some selected nonsteroidal antiinflammatories. Drug Dev Ind Pharm 1983; 9: 767-793
• 24 Watts PJ, Davies MC, Melia CD. Microencapsulation using emulsification/solvent evaporation. Crit Rev Ther Drug Carrier Syst 1990; 7: 235-258
• 25 Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int J Pharm 1999; 181: 143-151
• 26 Gennaro AR. Remington’s pharmaceutical sciences. XVIII ed. Easton, PA: Mack Publishing Company; 1990: 1116
• 27 Bertol CD, Cruz AP, Stulzer HK et al. Thermal decomposition kinetics and compatibility studies of primaquine under isothermal and non-isothermal conditions. J Therm Anal Cal 2010; 102: 187-192
• 28 Verma RK, Garg S. Compatibility studies between Isosorbide Mononitrate and selected excipients used in the development of extended release formulations. J Pharm Biomed Anal 2004; 35: 449-458
• 29 Peres-Filho MJ, Nogueira Gaeti MP, de Oliveira SR et al. Thermoanalytical investigation of olanzapine compatibility with excipients used in solid oral dosage forms. J Therm Anal Cal 2011; 104: 255-260